

CorNotes

CVI SEMINAR SERIES

The next CVI-Research Division Seminar will be held on **Thursday, January 15, 2009 at 4:00 pm** in **The Van Kampen Conference Center, Building 110, Room 6274**. Our speaker will be:

Francisco Villarreal, M.D., Ph.D.
Professor of Medicine
University of California – San Diego
San Diego, CA

The title of Dr. Villarreal's seminar is:

"The Cardioprotective Effects of Cocoa Flavanols"

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

January 8..... Dr. Margaret Prechel

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Rm. 5215. For further information, contact Dr. Ken Byron at x72819.

CARDIOLOGY – CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

January 22.....Dr. Leanne Cribbs

The title of Dr. Cribbs's talk is:

"Stem Cell Therapy: A Viable Alternative?"

For more information about this seminar series, contact Dr. Samarel at x72821.

RECENT PUBLICATIONS FROM THE CVI

Walenga JM, Bounameaux H, Ikeda Y (guest editors). Landmarks in Anti-Thrombin Drug Development – The Argatroban Story. *Seminars in Thrombosis and Hemostasis* 2008;34(Suppl 1).

Walenga JM, Bick RL, Messmore HL. Antigenic (immunogenic) profiling of bovine thrombin and its purified forms. Editorial. *Clin Appl Thromb Hemost* 2008;14(2):133-134.

Walenga JM, Drenth AF, Mayuga M, Hoppensteadt DA, Prechel MM, Harder S, Watanabe H, Osakabe M, Breddin HK. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. *Clin Appl Thromb Hemost* 2008;14(3):325-331.

Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M. Rivaroxaban – an oral, direct factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopenia. *Br J Haematol* 2008;143:92-99.

Walenga JM, Bounameaux H, Ikeda Y. Preface. Landmarks in anti-thrombin drug development: the argatroban story. *Semin Thromb Hemost* 2008;34(Suppl 1):1-2.

Hoppensteadt DA, Jeske W, Walenga JM, Fareed J. The future of anticoagulation. *Semin Respir Crit Care Med* 2008;29(1):90-99.

Untch BR, Jeske WP, Schwartz J, Botkin S, Prechel M, Walenga JM, Bakhos M. Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. *Clin Appl Thromb Hemost* 2008;14(2):141-148.

Prechel M, Walenga JM. Update of the laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia. *Semin Thromb Hemost* 2008;34(1):86-96.

Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. *Semin Thromb Hemost* 2008;34(1):74-85.